Medicovestor and Sanyou Biopharmaceuticals forge strategic partnership to develop first-in-class chemoimmunotherapy antibody-drug conjugates

CAR-T Digest - August 2020

Weekly Digest - June 2025

10 June 2025: Medicovestor and Sanyou Biopharmaceuticals forge strategic partnership to develop first-in-class chemoimmunotherapy antibody-drug conjugates 

Medicovestor and Sanyou Biopharmaceuticals have formed a strategic partnership to co-develop first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs)
The collaboration combines Medicovestor’s proprietary ADC platforms (ADoBind and ADoTope) with Sanyou’s AI-powered antibody library and drug screening technologies
Their joint effort aims to advance innovative ADCs for oncology and autoimmune diseases, focusing on enhanced efficacy and combination therapies
Medicovestor’s lead program targeting pancreatic cancer is in the IND-enabling stage, with an FDA Orphan Drug Designation application submitted